Rabbit anti-thymocyte globulin administration to treat rejection in simultaneous pancreas and kidney transplant recipients with recent COVID-19 infection.

Noveroske ShannaAsif A SharfuddinJohn PowelsonMuhammad YaqubOluwafisayo O AdebiyiCole BeelerAndrew LutzJonathan A Fridell

Published in: Clinical transplantation (2021)

Transplant recipients may be more susceptible to COVID-19 and itsrelated complications.1-3 Despite most patients being managed with reduction of immunosuppression, the risk of rejection or graft loss does not seem to be increased during COVID-19.

Keyphrases

end stage renal disease
coronavirus disease
ejection fraction
newly diagnosed
sars cov
chronic kidney disease
risk factors